Pharma Focus Asia

Merck Invests US$715 million in New Facility at Madison,USA

Merck with an investment of US$715 million plans for the expansion of Antibody-drug Conjugates (ADC) manufacturing. The new manufacturing facility will be located in Madison, Wisconsin, USA.

Antibody-drug Conjugates (ADC) manufacturing facility will be designed with an area covering 6,500-square-meter. This new facility will be engaged in the production of high-potent active pharmaceutical ingredients (HPAPI) and ADC manufacturing capabilities.

The project designed with a large area will be one of the largest manufacturing facilities to manage single-digit nanogram occupational exposure limit materials and support the continuous flow manufacturing of HPAPIs. Moreover, the new facility will be an addition to the first commercial ADC facility in North America specialised in ADC bio-conjugation, active pharmaceutical ingredients, excipient and adjuvants manufacturing.

The completion of the project is scheduled to be in the mid of 2022 and is expected to create 50 full-time jobs in the starting of 2021.


BudgetUS$715 million


magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference